On September 17, 2020, Vancouver Nanomedicine Day was delivered for the first time entirely online. Event organizer Dr. Urs Häfeli, of the Faculty of Pharmaceutical Sciences at UBC, hosted the 7.5 hour pageant of nanomedicine research on Zoom, with speakers and participants joining from around the globe. Of the 840… Read More »NMIN features prominently in Vancouver Nanomedicine Day 2020
NMIN researcher Dr. Ellen Wasan and colleagues have been awarded a five-year CIHR Project Grant worth $745,876 to support and expand upon her NMIN-funded project, “Intranasal Vaccines for Pertussis and Influenza Using Novel Formulations of a Triple Adjuvant.” The research aims to develop better vaccines—expanding the range of those who… Read More »Dr. Ellen Wasan receives a $745K CIHR grant to support her NMIN project
NMIN researcher Dr. Sarah Hedtrich, her team including NanoCore`s Operational Lead Dr. Dominik Witzigmann, discuss the status of gene therapies as tools for treating skin disease in a review article published in Trends in Biotechnology. “In this review, we discuss current approaches, successes, and failures of cutaneous gene therapy and… Read More »NMIN researchers discuss gene therapies for skin disease
NMIN researchers and colleagues have discovered a nanoparticle threshold dose that improves nanoparticle delivery and therapy for solid tumours. Published in Nature Materials, the study emerged from Dr. Warren Chan‘s Integrated Nanotechnology & Biomedical Sciences Laboratory at the University of Toronto, with NMIN researchers Drs. Chan and Gang Zheng as… Read More »NMIN researchers discover dose threshold for nanoparticle tumour delivery
In a new review article in Human Gene Therapy, NMIN researcher Dr. Colin Ross and NMIN HQP Tiffany Carlaw and Lin-Hua Zhang provide an overview of the current state of CRISPR/Cas9 base and prime editing technologies. “Therapeutic base editing is one form of genome engineering that has gained much interest… Read More »NMIN researchers discuss the current state of CRISPR/Cas9 editing
Using lipid nanoparticles (LNPs), NMIN research leaders Drs. Pieter Cullis and Christian Kastrup, together with colleagues at The University of British Columbia (UBC), have developed a new tool that can inhibit the activity of a blood protein involved in thrombosis and a number of other afflictions. The protein in question,… Read More »NMIN researchers: A new nanomedicine treatment for thrombosis?
The NanoMedicines Innovation Network (NMIN) is pleased to announce the third recipient of an NMIN-Mitacs Internship. In an internship of one year’s duration, Dr. Farahnaz Fathordoobady, NMIN HQP and Postdoctoral Fellow at the University of British Columbia (UBC), will collaborate with Ascension Sciences Inc. (ASI) to develop a novel oral… Read More »NMIN-Mitacs Intern developing novel cannabinoid delivery platforms
The NanoMedicines Innovation Network (NMIN) is pleased to announce the inaugural recipients of NMIN-Mitacs Internships: Drs. Kent Chen and Brian Hsu will both work with Cuprous Pharmaceuticals Inc. (CPI) on the development of novel nanomedicines to induce anticancer immunity, using CPI’s proprietary Metaplex technology. Dr. Kent Chen Dr. Brian Hsu… Read More »Inaugural NMIN-Mitacs Internships at Cuprous Pharmaceuticals Inc.
In a new review article published in Advanced Drug Delivery Reviews, NMIN researchers and colleagues discuss the use of state-of-the-art lipid nanoparticle (LNP) technology for therapeutic gene regulation in the liver. LNP technology enables the delivery of nucleic acids to treat liver diseases, addressing the root causes of these diseases… Read More »Lipid nanoparticle technology: poised to have a revolutionary impact
On March 31, 2020, NMIN’s Board of Directors approved a second round of research investment, supporting nine new projects—two within each of NMIN’s Research Themes (Targeted Drug Delivery, Gene Therapy, and Diagnostics), and three Strategic Initiatives. These new projects and initiatives, listed below by Research Theme, added 22 researchers and… Read More »Update: NMIN makes nine new research investments